Literature DB >> 14733945

Annexin-I expression modulates drug resistance in tumor cells.

Ying Wang1, Lucile Serfass, Marie Odile Roy, Judy Wong, Anne Marie Bonneau, Elias Georges.   

Abstract

The use of anti-cancer chemotherapy often leads to the rise of multidrug-resistant (MDR) tumors. We have previously reported the overexpression of a 40kDa protein (P-40) in several MDR tumor cell lines. In this report we describe the cloning of a 1.4kb cDNA with an open reading frame of 344 amino acids that encodes the P-40 protein. Analysis of the P-40 amino acid sequence showed it is identical to the human annexin I (Anx-I) protein. The identity of the isolated P-40 cDNA as Anx-I was confirmed by the specific binding of IPM96 mAb to a 40kDa protein following the in vitro expression of P-40 full-length cDNA. Northern blot analysis of total RNA from drug-sensitive and -resistant cells revealed an increase in P-40 (or Anx-I) mRNA in drug-resistant cells relative to drug-sensitive cells. Transfection of Anx-I cDNA into drug-sensitive MCF-7 cells was carried out without further drug selection and showed 2- to 5-fold increase in resistance of transfected cells to adriamycin, melphalan, and etoposide. Conversely, transfection of reverse Anx-I cDNA into SKOV-3 cells decreased the expression of Anx-I without affecting the expression of other members of the annexin family and showed a 3- to 8-fold increase in sensitivity to these drugs. Of interest was the correlation between the presence of Anx-I and MDR in MDA-MB-231 cells when compared to MCF-7 cells. MDA-MB-231 cells show 3- to 20-fold increase in resistance to adriamycin, melphalan, and etoposide in the absence of detectable levels of P-glycoprotein (P-gp1), the multidrug resistance protein (MRP1) or the breast cancer resistance protein (BCRP). Taken together, these results provide the first direct evidence for the role of Anx-I in MDR of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14733945     DOI: 10.1016/j.bbrc.2003.12.117

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Annexin A1 regulates intestinal mucosal injury, inflammation, and repair.

Authors:  Brian A Babbin; Mike G Laukoetter; Porfirio Nava; Stefan Koch; Winston Y Lee; Christopher T Capaldo; Eric Peatman; Eric A Severson; Roderick J Flower; Mauro Perretti; Charles A Parkos; Asma Nusrat
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.

Authors:  Yunliang Chen; Michael Scully; Gloria Petralia; Ajay Kakkar
Journal:  Cancer Biol Ther       Date:  2013-11-19       Impact factor: 4.742

3.  Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells.

Authors:  R Jesnowski; Dmitri Zubakov; Ralf Faissner; Jörg Ringel; Jörg D Hoheisel; Ralf Lösel; Martina Schnölzer; Matthias Löhr
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells.

Authors:  Nish Patel; Sabarni K Chatterjee; Vladimir Vrbanac; Ivy Chung; Chunyao Jenny Mu; Rachelle R Olsen; Carol Waghorne; Bruce R Zetter
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

5.  Expression of genes and proteins of multidrug resistance in gastric cancer cells treated with resveratrol.

Authors:  Katarzyna Mieszala; Malgorzata Rudewicz; Agnieszka Gomulkiewicz; Katarzyna Ratajczak-Wielgomas; Jedrzej Grzegrzolka; Piotr Dziegiel; Sylwia Borska
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

6.  Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.

Authors:  Shuang Liu; Young-Seung Kim; Shizhen Zhai; Jiyun Shi; Guihua Hou
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

Review 7.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

8.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Authors:  Jin Song; Ie-ming Shih; Daniel W Chan; Zhen Zhang
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

Review 9.  Biological modulation by lectins and their ligands in tumor progression and metastasis.

Authors:  Susumu Nakahara; Avraham Raz
Journal:  Anticancer Agents Med Chem       Date:  2008-01       Impact factor: 2.505

10.  Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells.

Authors:  Baofeng Zhao; Bo Xu; Wenquan Hu; Chunxia Song; Fangjun Wang; Zhong Liu; Mingliang Ye; Hanfa Zou; Qing R Miao
Journal:  J Proteomics       Date:  2014-08-27       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.